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Women suffering from breast cancer often succumb to incurable recurrent disease resulting from therapy-
resistant cancer cells. In this issue of Cancer Cell, Alvarez and colleagues identify downregulation of the
tumor suppressor Par-4 as the key determinant in apoptosis evasion, which leads to tumor recurrence in
breast cancer.Breast cancer is the second leading
cause of cancer deaths in women. It is
estimated that in the US alone, more
than 200,000 women will be diagnosed
and more than 20% will die of breast
cancer in 2013 (Siegel et al., 2013). Surgi-
cal intervention in conjunction with
chemotherapeutic agents generally pro-
vides distinct benefits to patients with
localized primary tumors, especially those
that have been detected early. Breast
cancer patients with positive estrogen re-
ceptor (ER), progesterone receptor (PR),
and/or human epidermal growth factor
receptor 2 (HER2) status are also respon-
sive to targeted therapeutics given as
monotherapy, such as trastuzumab, bev-
acizumab, or cetuximab, or in combina-
tion with chemotherapy (Alvarez et al.,
2010). Moreover, polychemotherapy
that includes cyclophosphamide, metho-
trexate, and fluorouracil or anthracy-
cline-based regimens combined with
taxanes has met with considerable suc-
cess in prolonging survival and delaying
breast cancer recurrence (Martin et al.,
2013). However, one in five patients ex-
hibits relapse of the disease within 10
years after treatment (Brewster et al.,
2008). In addition, about 20% of newly
diagnosed breast cancer cases present
with triple-negative status, which is
defined by loss of ER, PR, and HER2
(Metzger-Filho et al., 2012), and more
than 50% of primary tumors change their
hormone receptor status from ER-posi-
tive, PR-positive to ER-negative, PR-
negative at the time of recurrence
(Thompson et al., 2010). Breast cancers
with triple-negative or basal-like charac-teristics are often associated with a high
risk of metastasis and both local and
distant recurrence compared to receptor
positive tumors (Ahmad, 2013). Treatment
of such recurrent breast tumors is
challenging owing to their aggressive
nature, as they tend to be resistant to
the ‘‘standard of care’’ adjuvant or neo-
adjuvant systemic therapies. Conse-
quently, patients with recurrent disease
have low median survival. Despite the
alarming statistics on recurrent breast tu-
mors, the development of effective treat-
ment modalities has been severely
hampered by the paucity of data on the
therapy-resistant traits of such tumors.
There exists an urgent need for more
effective breast cancer prognosis to aid
the judicious treatment of tumors that
are most likely to recur.
The report by Alvarez et al. (2013) in
this issue of Cancer Cell transcends
many of these foregoing limitations and
provides timely insight into the molecular
basis of breast cancer recurrence. In this
seminal paper, the authors present
compelling evidence that downregulation
of the pro-apoptotic tumor suppressor
prostate apoptosis response-4 (Par-4)
(Hebbar et al., 2012) is a major determi-
nant underlying breast cancer recur-
rence. Although Par-4 was first described
in prostate cancer, it is ubiquitously
expressed and serves as a tumor sup-
pressor in diverse tumor types (Hebbar
et al., 2012). Based on a highly refined
analysis of gene expression records
from human breast cancer data sets
and the I-SPY 1 trial, Alvarez et al.
(2013) conclude that low levels ofCancerPar-4 expression result in significantly
decreased recurrence-free survival.
Elegantly designed cell culture and
mouse tumor experiments by Alvarez
et al. (2013) indicate that primary breast
tumors consist of a heterogeneous popu-
lation of cancer cells, especially with
regard to Par-4 expression (Figure 1).
Tumor cells expressing high levels of
Par-4 are eliminated by apoptosis
following oncogene inhibition or chemo-
therapy, whereas those expressing low
levels of Par-4 show an increased propen-
sity to recur at both local and distant
metastatic sites. Par-4 downregulation
was particularly associated with all breast
cancer traits that confer poor prognosis,
such as ER-negative status, basal-like
subtype, and high grade (grade III). By
using primary and recurrent murine
tumors driven by HER2/neu, MYC, or
WNT1 oncogenic signaling, the authors
demonstrate that tumors that relapse af-
ter oncogene inhibition or chemotherapy
exhibit significantly diminished levels of
Par-4 RNA and protein. Moreover, using
orthotopic tumors with either low levels
of Par-4 caused by short hairpin-RNA
knockdown or overexpressed Par-4 via
retroviral transduction, the authors dem-
onstrate that downregulation of Par-4
is essential for tumor recurrence. By con-
trast, Par-4 levels do not influence primary
tumor formation. The observations on the
three distinct clinically relevant mouse
models therefore recapitulate the findings
of the meta-analysis on human breast
cancer gene expression profiles. Thus,
oncogene inhibition or chemotherapeutic
regimens select for pre-existing tumorCell 24, July 8, 2013 ª2013 Elsevier Inc. 3
Figure 1. Par-4 Expression Is a Key Determinant of Breast Cancer Recurrence
Primary breast tumors display heterogeneity in expression profiles for Par-4 and SNAIL. Breast tumor cells
with higher SNAIL transcription factor activity undergo EMT and metastasize. Oncogene inhibition or
chemotherapy of primary or metastatic breast tumors causes Par-4-dependent apoptosis for cancer cells
expressing normal levels of Par-4 via multinucleation, which is dependent on ZIP kinase and MLC2
activation. On the other hand, primary or metastatic breast tumor cells expressing low levels of Par-4
(i.e., below a critical threshold) evade apoptosis; such cells constitute recurrent tumors at both local
and distant sites.
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Previewscells that express low levels of Par-4,
which are below the critical threshold for
induction of apoptosis, and such cells
constitute the therapy-resistant popula-
tion that emerges as a recurrent tumor.
It is noteworthy that the expression of
endogenous Par-4 as well as ectopic
Par-4 is suppressed in recurrent tumors.
Similar observations were previously
made in the prostate of mice coexpress-
ing oncogenic SV40 antigens and the
SAC transgene, which represents the
killer domain of Par-4 (Zhao et al., 2007).
Zhao et al. (2007) found that when the
SAC transgene was spontaneously elimi-
nated from benign areas of the prostate
prostatic adenocarcinoma developed,
whereas prostatic epithelial cells that
continued to express the SAC domain re-
mained normal or benign. These findings
not only reiterate the tumor suppressor
potential of Par-4, but they also reaffirm
that Par-4 induces apoptosis specifically
in malignant tumor cells, not normal or
benign cells.
The findings of Alvarez et al. (2013) on
tumor recurrence also shed light on the4 Cancer Cell 24, July 8, 2013 ª2013 Elseviedistinct roles for Par-4 and other key pro-
teins WNT and SNAIL, which have been
previously shown to regulate EMT and
metastasis. Unlike SNAIL and WNT,
which have been reported to be over-
expressed or activated in breast cancer
EMT, metastasis, and recurrence
(Ahmad, 2013), low Par-4 levels do not
cause EMT or metastasis per se, permit-
ting breast cancer recurrence indepen-
dent of these traits by evading apoptosis.
Importantly, the authors show that down-
regulation of Par-4 is necessary and suffi-
cient for recurrence and occurs indepen-
dently of SNAIL. Future studies on the
mechanism by which Par-4 is downregu-
lated in breast tumors may further unravel
the molecular network involved in Par-4
regulation and breast cancer recurrence.
Mechanistically, increased Par-4 ex-
pression in tumor cells in response to
oncogene inhibition or treatment with
chemotherapeutic agents was shown to
enhance ZIP kinase-induced phosphory-
lation of MLC2 and multinucleation, ulti-
mately leading to tumor cell apoptosis.
Because the induction of tetraploidy isr Inc.tumorigenic in a p53-deficient back-
ground, an intact p53 pathway is most
likely required for this response. Although
ZIP kinase has been previously shown to
interact with Par-4, it is plausible that
direct binding to Par-4 may not be neces-
sary to provoke the ZIP kinase-dependent
MLC2 phosphorylation and cytokinesis
failure in breast cancer. Consequently,
unlike tumor cells expressing basal levels
of Par-4 that are readily eliminated by
chemotherapy or oncogene inhibition,
tumors expressing low Par-4 levels fail
to elicit the ZIP kinase-driven apoptotic
response and therefore constitute local
or distant recurrent disease. Although
the role of Par-4 in inducing apoptosis
has been well characterized in the
broader cellular context (Hebbar et al.,
2012), this manuscript demonstrates an
atypical mechanism for apoptosis by
Par-4 in oncogene-addicted cells. These
findings offer a new mechanistic link
between oncogene addiction, Par-4 regu-
lation, and tumor recurrence.
In summary, Alvarez et al. (2013) pro-
vide crucial insights into the heterogeneity
of breast cancer and suggest that Par-4
is a viable prognostic marker for breast
cancer recurrence. Their findings may
provide the basis for the development of
novel treatment strategies for breast can-
cer, such as nanotechnology, to deliver
recombinant Par-4 to tumors in order to
replenish intracellular Par-4 levels and
sensitize the tumors to the action of ther-
apeutics, whichmay prolong disease-free
survival in breast cancer patients.
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Identification of tractable signaling molecules essential for leukemogenesis facilitates the development of
effective targeted therapies. In this issue of Cancer Cell, Miller and colleagues report that Integrin Beta 3,
which is largely dispensable for normal hematopoiesis, plays an important role and is a potential therapeutic
target in mixed lineage leukemia.Acutemyeloid leukemia (AML) is a hetero-
geneous clonal disorder of hematopoietic
stem and progenitor cells characterized
by the presence of recurring chimeric
transcription factors and/or mutations
affecting key components of the tran-
scription machinery. With the exception
of acute promyelocytic leukemia, which
is uniquely sensitive to targeted therapies
using all-trans retinoic acid and arsenic
trioxide, treatment for other AML has not
changed in the past decades, and thus
AML remains a highly fatal disease with
very poor overall survival rates (Zeisig
et al., 2012). Among them, recurrent
genetic abnormalities involving chimeric
fusion of the mixed lineage leukemia
(MLL) gene at chromosome 11q23 repre-
sents one of the worst prognostic AML
subgroups and urgently needs the devel-
opment of novel and effective therapeutic
interventions. Given the important role of
MLL fusions in initiating and maintaining
the disease, major effort has been made
in dissecting the molecular functions of
these initiating events. As a result, a
number of critical molecules associated
with MLL fusion transcription complexes,
including various epigenetic modifying
enzymes, have been identified and
demonstrated as potential therapeutic
targets forMLL (Figure 1A). In spite of their
promise in preclinical disease models, thedevelopment of specific inhibitors target-
ing the transcription machinery is still in
a very early phase and a bottleneck for
translating these results into the clinics.
Approaches in identifying more tractable
signaling molecules in which small-mole-
cule inhibitors are readily available there-
fore appear as attractive alternatives.
In this issue of Cancer Cell, Miller et al.
(2013) reported their in vivo shRNA
screening approach to identify novel reg-
ulators required for MLL-AF9 leukemia in
a mouse model with a focused library tar-
geting 268 known or candidate cancer-
associated genes. Using massively
parallel sequencing to determine the rela-
tive distribution of each shRNA at different
time points, 60 candidate genes targeted
by at least two different shRNAs were
found to be significantly depleted in vivo.
Among them were Ctnnb1, Myb, and
Mef2c, which have been previously
shown as critical targets for MLL. In addi-
tion, Itgb3 was also among the most
highly depleted, suggesting that Itgb3
could represent a novel target for MLL-
AF9 leukemia. Its functional significance
was further validated with individual
shRNAs targeting Itgb3, which resulted
in a significant delay of the AML disease
onset in recipient mice. Integrins are
known to mediate many cellular pro-
cesses and interact with the micro-environment. Consistently, the authors
showed that leukemic cells with a
reduced level of Itgb3 had a compro-
mised ability to home and engraft in the
bone marrow upon transplantation in
both mouse and humanized xenograft
models. On the other hand, successfully
engrafted MLL cells carrying Itgb3 shRNA
progressively declined over time, indi-
cating a critical function of Itgb3 in medi-
ating leukemic proliferation in addition to
homing. The pathological importance of
Itgb3 signaling in MLL-AF9 leukemia was
further demonstrated by the depletion of
leukemic clone with shRNAs targeting its
heterodimeric partner, Itgav. Interestingly,
the loss of Itgb3 is largely dispensable for
normal hematopoiesis as Itgb3 germline
knockout mice show no obvious hemato-
poietic defect and human patients with
biallelic ITGB3 mutation do not have a
bone marrow failure phenotype. In terms
of homing, Itgb3 knockdown did not
impair hematopoietic reconstitution of
normal LSK cells over a 24-week period
after transplantation, although confirma-
tion of persistent Itgb3 knockdown in the
transplanted cells was not demonstrated.
Nevertheless, these data together reveal
Itgb3 as a novel therapeutic target for
MLL (Figure 1B).
To gain further mechanistic insight into
Itgb3 signaling in AML, a secondary in vivoCell 24, July 8, 2013 ª2013 Elsevier Inc. 5
